Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

AbbVie must reimburse AndroGel overcharges

Reprints

A U.S. District Court judge in Philadelphia has ruled that pharmaceutical firm AbbVie Inc. must pay $448 million in monetary relief to consumers who were allegedly overcharged for a testosterone replacement drug, in a case filed by the Federal Trade Commission.

The company said in a statement that it intends to appeal the ruling.

The FTC said in a statement Friday that the North Chicago, Illinois-based pharmaceutical firm had used sham litigation to illegally maintain its monopoly over AndroGel. The FTC said the court order represents the largest monetary award ever in a litigated FTC antitrust case.

The FTC said it had filed its complaint in 2014, charging that AbbVie and its partner, Bangkok-based Besins Healthcare Inc., illegally blocked American consumers’ access to lower-cost alternatives to AndroGel by filing baseless patent infringement lawsuits against potential generic competition.

FTC chairman Joe Simons said in the statement: “This decision is a double victory, both for patients who rely on AndroGel and for competition more broadly. It sends a clear signal that pharmaceutical companies can’t use baseless litigation to forestall competition from low-cost generics.”

The company said in a statement: “We are disappointed by the ruling. We believe our conduct was lawful and the damages award is improper. We intend to appeal.”

In January, a federal jury found AbbVie not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using AndroGel. 

Read Next

  • AbbVie wins trial in lawsuit over AndroGel risks

    (Reuters) — A federal jury in Chicago on Friday found AbbVie Inc. not liable in a lawsuit by an Arizona man who claimed he had suffered a pulmonary embolism due to using the company's testosterone replacement medication AndroGel.